Amgen Inc
Biotechnology
Amgen Inc (AMGN) Stock News
The latest AMGN headlines and market coverage — 4 recent stories, updated throughout the day.
- Zacks Investment Research·Neutral
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
Amgen stock gained 2.6% to close at $413.08, outperforming the broader market decline. The biotech giant is projected to report EPS of $5.69 (up 0.89% YoY) and revenue of $9.91 billion (up 3.68% YoY). For the full year, consensus estimates project earnings of $22.94 per share and revenue of $38.81 billion. Amgen holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 17.55, trading at a discount to its industry average.
- Zacks Investment Research·Neutral
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen has recently been a trending stock, with shares down 7.8% over the past month compared to the S&P 500's +0.8% gain. The biotech company shows solid fundamentals with consistent earnings and revenue beat history, but the Zacks Rank #3 (Hold) rating suggests it may perform in line with the broader market in the near term. Current year earnings are expected to grow 5% with revenue growth of 5.6%, while the stock trades at par with peers based on valuation metrics.
- Zacks Investment Research·
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Amgen's MariTide is entering a competitive obesity market dominated by Novo Nordisk and Eli Lilly. The drug showed up to 20% average weight loss in phase II trials and offers a key advantage with once-monthly or less-frequent dosing compared to weekly injections from competitors. While MariTide trails competitors' efficacy and market presence, the massive obesity market projected to reach $114 billion by 2030 could support multiple players, allowing MariTide to carve out a meaningful position based on convenience and adherence.
- Yahoo Finance·Bullish
Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings